Posted by Michael Wonder on 23 Mar 2024
Deliberations at the CHMP regarding the marketing authorisation application in the EU for lecanemab have been rescheduled due to procedural reasons at the EMA
22 March 2024 - Eisai announced today that the oral explanation scheduled for 19 March at the CHMP for lecanemab, which is currently under review by the EMA, did not take place due to procedural reasons at the EMA.
On 14 March 2024, the Court of Justice of the European Union ruled on the organisation of EMA’s Scientific Advisory Groups attendance.
